AbbVie (ABBV): 135 IPR Hearing Shifted Odds Favourably - Jefferies

February 17, 2017 7:23 AM EST Send to a Friend
Jefferies analyst, Jeffrey Holford, reiterated his Buy rating on shares of Abbvie (NYSE: ABBV) along with his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login